For nearly three decades, Genentech has been the sole provider of an approved medication for acute stroke treatment. On 03 March 2025, the Roche subsidiary expanded its stroke treatment portfolio with FDA approval for TNKase (tenecteplase).
TNKase (tenecteplase) is a thrombolytic, clot-dissolving tissue plasminogen activator. Administered as a single five-second intravenous bolus, it triggers a biochemical reaction that breaks down fibrin, a key component of blood clots. The most common side effects of tenecteplase include bleeding and hypersensitivity. TNKase is now approved for treating acute ischemic stroke (AIS) in adults, with dosing guidelines rec...
